MEGAPORT-LIMITED
14.12.2021 23:02:07 CET | Business Wire | Press release
Megaport Limited (ASX: MP1) ("Megaport"), a global leading Network as a Service (NaaS) provider, today announces the availability of VMware SD-WAN on Megaport Virtual Edge (MVE). VMware SD-WAN’s will be interoperable with MVE to enable branch-to-cloud connectivity on Megaport’s global Software Defined Network (SDN).
Optimising VMware SD-WAN Connectivity
Many businesses have embraced SD-WAN and internet connections as a means of simplifying their IT connectivity. With VMware SD-WAN available on MVE, customers can host localised virtual SD-WAN controllers on Megaport’s global platform and reduce the distance data traverses over internet paths from branch locations to critical services in public or private clouds and even other branch locations.
Once connected, VMware customers can access Megaport’s leading ecosystem of more than 700 enabled data centres worldwide and over 360 service providers, including 220+ cloud on-ramps from the world's leading clouds such as Alibaba Cloud, AWS, Google Cloud, Microsoft Azure, IBM Cloud, Oracle Cloud, and Salesforce.
VMware SD-WAN on MVE Highlights:
- Reduced cloud egress costs to cloud on-ramps when compared to internet rates.
- Globally distributed for localised connections.
- Point-and-click network provisioning to support interconnection between branch locations, data centres, cloud providers, and IT services.
- Real-time provisioning of virtual network infrastructure and interconnections.
- No hardware to ship, install, or manage.
- Unified end-to-end network provisioning and management to transform legacy networks.
- More secure, multi-cloud connections to more than 360 service providers, 700+ enabled data centres, and 220+ cloud interconnect points.
Craig Connors, vice president and general manager at VMware, said, “VMware SD-WAN in combination with Megaport Virtual Edge offers customers more choice for simplifying WAN operations, reliable network performance for business-critical applications, and easier adoption of hybrid cloud and multi-cloud, while reducing latency to cloud workloads.”
Transforming Networking at the Edge
MVE is a globally distributed compute and network service in one. The compute aspect of the service enables customers to host NFV instances in locations where they need them, on demand, and manage them in a point-and-click manner. On the network side, MVE’s built-in transit gateway provides a highly scalable access point for connecting networks, via the public internet, to Megaport’s private SDN. Virtualised devices hosted on MVE can utilise the transit gateway to create connections between the Megaport SDN and their own networks, including branch locations, data centres, and private clouds.
MVE is available in 24 metros across North America, Asia-Pacific, and Europe. This allows customers more flexibility to deploy virtual devices near concentrations of users to localise traffic and optimise data termination for performance.
“As enterprises and service providers rapidly adopt SD-WAN technology to improve edge network connectivity, the ability for Megaport customers to easily, and in minutes, ‘spin up’ VMware SD-WAN edge routers around the world on our platform is a big enabler for global organisations,” said Vincent English, CEO of Megaport. “Having VMware SD-WAN in Megaport’s global Software Defined Network allows our customers to optimise their SD-WAN connectivity to improve overall network and application performance at a fraction of the cost of legacy methods.”
For more information about Megaport Virtual Edge, please visit https://www.megaport.com/mve .
For more information about VMware SD-WAN, learn more at https://sdwan.vmware.com/ .
VMware and VMware SD-WAN are registered trademarks or trademarks of VMware, Inc. or its subsidiaries in the United States and other jurisdictions.
About Megaport
Megaport is a leading provider of Network as a Service (NaaS) solutions. The company’s global Software Defined Network (SDN) helps businesses rapidly connect their network to services via an easy-to-use portal or our open API. Megaport offers agile networking capabilities that reduce operating costs and increase speed to market compared to traditional networking solutions. Megaport partners with the world’s top cloud service providers, including AWS, Microsoft Azure, and Google Cloud, as well as the largest data centre operators, systems integrators and managed service providers in the world. Megaport is an ISO/IEC 27001-certified company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005135/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom